Hépato-Gastro & Oncologie Digestive


NS5A inhibitors with sofosbuvir: place in the management of genotype 3 patients Volume 23, supplement 1, Février 2016


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

  • Figure 5
Hôpital Henri Mondor, service d’hépatologie, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France ; Université Paris-Est, Créteil, France
* Tirés à part

The treatment of patients with genotype 3 chronic hepatitis C is mainly based on the use of a NS5A inhibitor in combination with Sofosbuvir. The best strategy in terms of efficacy and safety is sofosbuvir and daclatasvir for all genotype 3 patients. However, the optimal strategy varies according to the severity of the disease. This regimen is given for 12 weeks without ribavirin in non-cirrhotic patients, allowing achieving a SVR in more than 95 % of the cases. In patients with compensated cirrhosis, two options could be proposed: 12 weeks with ribavirin or 24 weeks without ribavirin and the SVR rates are around 90%. Finally, in patients with decompensated cirrhosis, the ideal regimen remains not clearly defined and the recommendation is to treat for 24 weeks with ribavirin. In conclusion, daclatasvir is one of the backbones for the treatment of patients infected with genotype 3.